BCRX

Business Context and Reporting Period

Company: BioCryst Pharmaceuticals, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: BioCryst is a biotechnology company focused on structure-based drug design to develop small-molecule pharmaceuticals for cancer, viral infections, and autoimmune diseases. The company's primary assets are peramivir (an influenza neuraminidase inhibitor) and forodesine (a PNP inhibitor for T-cell lymphomas). The company has not yet achieved profitability and relies on government contracts, collaborative agreements, and equity financing.

Key Financial Metrics

Liquidity: As of December 31, 2009, the company held $94.3 million in cash and marketable securities. Management estimates these resources, combined with expected future payments from collaborators, will fund operations for at least the next twelve months. The company reported a net cash burn of approximately $37.2 million for 2009 (excluding a $45.7 million equity offering and $22.5 million in HHS product sales).

Material Changes vs. Prior Period

• Revenue Increase: Total revenue increased 32% to $74.6 million. This was driven by:
  • Product Sales: $22.5 million in sales of i.v. peramivir to the U.S. Department of Health and Human Services (HHS) under an Emergency Use Authorization (EUA).
  • Milestone Payments: A $7.0 million regulatory milestone payment from partner Shionogi for the filing of a New Drug Application (NDA) in Japan.
  • HHS Contract: Increased revenue recognition from the HHS development contract due to the initiation of global Phase III studies.
• Net Loss Reduction: Net loss improved significantly from $24.7 million in 2008 to $13.5 million in 2009, primarily due to the revenue increases noted above.
• Inventory Reserve: The company recorded a $4.0 million provision (reserve) for peramivir finished goods inventory within Cost of Products Sold. Although the EUA allowed for capitalization of manufacturing costs, management determined there was no certainty of future sales to recover these costs, resulting in a full write-down.
• Equity Financing: In November 2009, the company completed a registered offering of 5 million shares, raising net proceeds of $45.7 million.

Guidance, Outlook, and Risks

Outlook and Guidance

• Cash Burn: Management expects cash use for 2010 to be between $25.0 million and $30.0 million.
• Peramivir (Influenza):
  • Two Phase III clinical trials for i.v. peramivir in hospitalized patients were initiated in September 2009 (target enrollment: ~700 patients).
  • Shionogi received marketing approval for i.v. peramivir (RAPIACTA) in Japan in January 2010, triggering a $7.0 million milestone payment expected in Q1 2010.
  • HHS has placed an initial order for 10,000 courses ($22.5 million) and may order up to 40,000 courses total under an Indefinite Delivery Indefinite Quantity contract.
• Forodesine (Oncology):
  • A pivotal Phase II trial for Cutaneous T-cell Lymphoma (CTCL) enrolled 100 late-stage patients in January 2010; top-line data expected in H2 2010.
  • Phase II trial for Chronic Lymphocytic Leukemia (CLL) is ongoing with top-line data expected in H2 2010.
• BCX-4208 (Gout): A Phase II trial for gout was initiated, with initial data expected in mid-2010.

Risks and Contingencies

• Profitability: The company has incurred losses since inception and expects to continue doing so. Future profitability depends on regulatory approval and commercialization.
• HHS Contract Dependency: A significant portion of revenue and cash flow depends on the HHS contract. The government can terminate the contract for convenience or default, which would negatively impact cash flows.
• Inventory Uncertainty: The full reserve on peramivir inventory highlights the risk that future demand may not materialize to cover manufacturing costs.
• Collaboration Risks: The company relies on partners (Shionogi, Mundipharma) for development and commercialization in key markets. Partner termination or failure to meet milestones would reduce potential revenue.
• Regulatory Risk: Clinical trials may fail to demonstrate safety or efficacy, or regulatory authorities may delay or deny approval.

Investor Verification Checklist

• HHS Contract Status: Verify the current status of the $179.9 million HHS contract and the likelihood of additional orders beyond the initial 10,000 courses.
• Peramivir Inventory: Confirm whether the $4.0 million inventory reserve remains necessary or if new orders justify capitalization of future manufacturing costs.
• Shionogi Milestone: Confirm receipt of the $7.0 million regulatory milestone payment from Shionogi following the January 2010 Japan approval.
• Cash Runway: Monitor quarterly cash burn rates against the $25-$30 million guidance for 2010 to assess the need for additional financing.
• Clinical Trial Enrollment: Track enrollment progress in the pivotal Phase III peramivir trials and the Phase II forodesine trials to ensure timelines for data readouts (H2 2010) are met.